Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01764646
Other study ID # 11-196
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 2012
Est. completion date September 2025

Study information

Verified date May 2020
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: It is not yet known whether extreme hypofractionation is equally safe and effective than standard radiation therapy in treating prostate cancer.

PURPOSE: This protocol presents a randomised phase II study aiming to investigate the tolerance and disease control of extreme hypofractionated Radiation Therapy for prostate cancer.


Description:

This protocol presents a randomised phase II study aiming to investigate the tolerance and disease control of extreme hypofractionated RT for prostate cancer by delivering 5 x 7.25 Gy = 36.25 Gy over two alternative time schedules: either over 9 days (study A), or over 28 days once-a-week, the same week-day (study B).

The total dose and fractionation schedules have been chosen based on the assumption of their isoeffectivity regarding potential late rectal effects to be expected with a maximum equivalent dose of 74 Gy in 2 Gy fractions and assuming an alpha/beta = 3 Gy for the rectum.

In both arms, the prescribed dose per fraction to the urethra and the surrounding transitional zone will be dropped from 7.25 Gy to 6.5 Gy with a simultaneous integrated boost (SIB) technique. A dose of 5 x 6.5 Gy is equivalent to 31 x 2 Gy assuming an alpha/beta = 3 Gy for the urethra and equivalent to 37 x 2 Gy assuming an alpha/beta = 1.5 Gy for microscopic tumour foci in the transitional zone surrounding the urethra. The two treatment regimens chosen will each be the object of a separate phase I-II study covered by the same protocol and performed in parallel by the participating centres. Randomised assignment to either of the two studies will be introduced to avoid selection bias in treatment assignment within each centre.

OBJECTIVES:

Primary

- To determine the risk of urinary, rectal and sexual acute and late toxicities rates in patients receiving two different time schedules of extreme hypofractionated radiation therapy

• Secondary

- To determine the Quality of life (EORTC QLQ-C30, Prostate cancer module EORTC QLQ-PR25) in patients receiving two different time schedules of extreme hypofractionated radiation therapy

- To determine the rate of local failure

- To determine in the two study arms the biochemical disease-free survival bDFS rate

- To determine in the two study arms the metastases-free survival rate

- To determine in the two study arms the disease-specific survival rate

OUTLINE:

This is a multicenter study.

Patients undergo extreme hypofractionated radiation therapy for prostate cancer by delivering 5 x 7.25 Gy = 36.25 Gy over two alternative time schedules:

Experimental Arm A: Over 9 days. Experimental Arm B: Over 28 days once-a-week, the same week-day. All patients will be followed up for at least 18 months to contribute to the analysis of the main endpoints of the study. With reference to the secondary endpoints, follow-up will be extended to 10 years.

Stopping rule: In order to avoid exposure of patients to a treatment that may be unsafe, acute GI and GU toxicity will be continuously monitored with the purpose of assisting in the decision of possibly interrupt recruitment in case of an alarming frequency.To this purpose, the procedure of Ivanova et al., 2005 will be applied.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 170
Est. completion date September 2025
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Age: >18

- WHO performance status = 2

- Any patient where prophylactic lymph node irradiation is not required, i.e. risk of nodal microscopic involvement = 20% (according to Roach et al (25):

"N+ (in %) = (Gleason score - 6) x 10 + 2/3 PSA at diagnosis)"

- T-stage: cT1-cT3a.

- Previous TURP is allowed provided there is at least 8 weeks interval with radiotherapy.

- Combined hormonal treatment (Neoadjuvant-concomitant androgen deprivation, AD, for 6 months) is mandatory if two or more of the following tumour characteristics are present: =cT2c, Gleason 4+3, PSA >10 ng/ml, perineural invasion, and/or >1/3 of positive biopsies. RT shall be delivered between 2 and 3 months (+/- 1 week) after starting AD and according to the following chronologic sequence:

1. Neoadjuvant AD for 2 months (30 days of bicalutamide 50mg qd, and a 3-month slow-releasing LH-RH analog to be started 15 days after initiating bicalutamide).

2. Randomization at the end of the neoadjuvant AD period (2 months after starting AD).

3. Planning RT (to be started within 1 month after randomization (i.e., between the 2nd and 3th month after initiating AD)

- Concomitant and adjuvant HT for 4 more months (a second 3-month slow-releasing LH-RH analog injection).

Exclusion Criteria:

- Inability to obtain a written informed consent

- Patient preference to be treated with one rather than the other treatment arm.

- WHO performance status > 2

- cT3b,cT4

- Gleason score =8

- Clinical N+ on metastases work-up or N+ risk >20% (Roach algorithm)

- Severe urinary obstructive symptoms (IPSS symptom index >19)

- Previous TURP less than 8 weeks before radiotherapy

- Previous prostate surgery other than TURP

Study Design


Intervention

Radiation:
Intensity modulated radiation therapy
Minimize radiation doses to surrounding area
Volumetric modulated arc therapy
Highly conformational dose distribution
Image guided radiation therapy
Follow target by the use of fiducial markers and ERB

Locations

Country Name City State
Belgium Onze Lieve Vrouwziekenhuis Aalst
Finland University Hospital Turku
Israel Sheba Medical Center Ramat Gan
Netherlands VU University Medical Center Amsterdam
Portugal Portuguese Institut of Oncology Porto
Spain Teknon Oncologic Institute Barcelona
Spain Hospital Universitario Sanchinarro Madrid
Switzerland University Hospital Geneva
Turkey Neolife Medical Center Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Thomas Zilli

Countries where clinical trial is conducted

Belgium,  Finland,  Israel,  Netherlands,  Portugal,  Spain,  Switzerland,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tolerance to treatment Tolerance to treatment (urinary, rectal, sexual): Acute (up to 90 days) and late (up to 5 years) toxicity follow-up according to NCI CTCAE version 3.0 up to 5 years
Secondary 1. Quality of life Quality of life (EORTC QLQ-C30, Prostate cancer module EORTC QLQ-PR25) 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
Secondary 2. Local failure Assessed by digital rectal examination (DRE). MRI or PET-CT with choline or acetate may be a confirmatory option. Biopsy confirmation is required for those patients with exclusive local failures and candidates for local salvage. 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
Secondary 3. Biochemical disease-free survival bDFS Phoenix definition (PSA nadir + 2 ng/ml) 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
Secondary 4. Metastases-free survival Outcomes 3 or 4 - investigations PET-CT choline 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
Secondary 5. Disease-specific survival Alive/dead status, date and cause of death and prostate cancer disease status (outcomes 3/4 and 5). 9 days (Treatment arm A) or 28 days (Treatment arm B), 12 weeks, 6, 12, 18 months and yearly thereafter, up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Suspended NCT04696263 - Single-Port Versus Multi-Port Robotic Radical Prostatectomy N/A
Recruiting NCT06150417 - MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) Phase 2
Withdrawn NCT04765423 - Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease N/A
Recruiting NCT06437496 - 68Ga-AAZTA-093 PET/CT: First-in-human Study Early Phase 1